EGFR and non-small cell lung carcinoma: MET amplification, pan-MET amplification, and polysomy accounted for 1%, 3%, and 19%, respectively, in our in-house cohort of 155 patients with untreated EGFR-mutated NSCLC (Fig. 4B).